OKYO
Pharma Limited

1,288
Loading...
Loading...
News
all
press releases
Buy Rating on OKYO Pharma: U.S. Patent and Strong Trial Results for OK-101 Boosts Market Potential
OKYO Pharma Limited Sponsored ADR (OKYO Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi...
TipRanks Financial Blog·1y ago
News Placeholder
More News
News Placeholder
OKYO Pharma Secures U.S. Patent for DED Therapy
OKYO Pharma Limited Sponsored ADR (OKYO) has released an update. OKYO Pharma Limited has announced the grant of a critical U.S. patent for OK-101...
TipRanks Financial Blog·1y ago
News Placeholder
OKYO Pharma Chairman Boosts Shareholding
OKYO Pharma Limited Sponsored ADR (OKYO) has released an update. OKYO Pharma Limited, a biopharmaceutical company focusing on ocular therapies, has...
TipRanks Financial Blog·1y ago
News Placeholder
OKYO Pharma Release Lacks Content
OKYO Pharma Limited Sponsored ADR (OKYO) has released an update. The news release from OKYO Pharma Limited Sponsored ADR appears to be a document e...
TipRanks Financial Blog·1y ago
News Placeholder
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
Globe Newswire·1y ago
News Placeholder
OKYO Pharma Limited (NASDAQ:OKYO) Short Interest Update
OKYO Pharma Limited (NASDAQ:OKYO - Get Free Report) saw a significant drop in short interest in March. As of March 15th, there was short interest totalling 50,800 shares, a drop of 21.4% from the...
Ticker Report·1y ago
News Placeholder
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
Ocular Pain Relief showed statistically significant improvement as early as day 15 and the benefit was durable throughout the trial.Conjunctival Staining improved as early as day 29 with a durable...
Globe Newswire·1y ago
News Placeholder
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
-Phase 2 OK-101 efficacy data to be released March 22nd, 2024- -KOL Event to be held on April 9th, 2024 at 12 PM ET- LONDON and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited...
Globe Newswire·1y ago
News Placeholder
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
LONDON and NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
Globe Newswire·1y ago
News Placeholder
OKYO Pharma Limited (NASDAQ:OKYO) Sees Large Decrease in Short Interest
OKYO Pharma Limited (NASDAQ:OKYO Get Free Report) was the target of a significant decline in short interest during the month of February. As of February 29th, there was short interest...
Ticker Report·2y ago

Latest OKYO News

View

Advertisement. Remove ads.

Advertisement. Remove ads.